Daniel Bradley
Cambridge, Massachusetts, United States
2K followers
500+ connections
About
Over 20 years experience working in the pharmaceutical industry specializing in late…
Activity
-
Great news! We’ve been named a top place to work in the industry for the third year in a row. This recognition is possible because Vertexians across…
Great news! We’ve been named a top place to work in the industry for the third year in a row. This recognition is possible because Vertexians across…
Liked by Daniel Bradley
Experience
Education
Publications
-
Molecular imaging of aurora kinase A (AURKA) expression: synthesis and preclinical evaluation of radiolabeled alisertib (MLN8237)
Nuclear medicine and biology
Introduction
Survival of patients after resection of colorectal cancer liver metastasis (CRCLM) is 36-58%. Positron emission tomography (PET) tracers, imaging the expression of prognostic biomarkers, may contribute to assign appropriate management to individual patients. Aurora kinase A (AURKA) expression is associated with survival of patients after CRCLM resection.
Methods
We synthesized [3H]alisertib and [11C]alisertib, starting from [3H]methyl nosylate and [11C]methyl iodide…Introduction
Survival of patients after resection of colorectal cancer liver metastasis (CRCLM) is 36-58%. Positron emission tomography (PET) tracers, imaging the expression of prognostic biomarkers, may contribute to assign appropriate management to individual patients. Aurora kinase A (AURKA) expression is associated with survival of patients after CRCLM resection.
Methods
We synthesized [3H]alisertib and [11C]alisertib, starting from [3H]methyl nosylate and [11C]methyl iodide, respectively. We measured in vitro uptake of [3H]alisertib in cancer cells with high (Caco2), moderate (A431, HCT116, SW480) and low (MKN45) AURKA expression, before and after siRNA-mediated AURKA downmodulation, as well as after inhibition of P-glycoprotein (P-gp) activity. We measured in vivo uptake and biodistribution of [11C]alisertib in nude mice, xenografted with A431, HCT116 or MKN45 cells, or P-gp knockout mice.
Results
[3H]Alisertib was synthesized with an overall yield of 42% and [11C]alisertib with an overall yield of 23±9% (radiochemical purity ≥99%). Uptake of [3H]alisertib in Caco2 cells was higher than in A431 cells (P=.02) and higher than in SW480, HCT116 and MKN45 cells (P<.01). Uptake in A431 cells was higher than in SW480, HCT116 and MKN45 cells (P<.01). Downmodulation of AURKA expression reduced [3H]alisertib uptake in Caco2 cells (P<.01). P-gp inhibition increased [3H]alisertib uptake in Caco2 (P<.01) and MKN45 (P<.01) cells. In vivo stability of [11C]alisertib 90 minutes post-injection was 94.7±1.3% and tumor-to-background ratios were 2.3±0.8 (A431), 1.6±0.5 (HCT116) and 1.9±0.5 (MKN45). In brains of P-gp knockout mice [11C]alisertib uptake was increased compared to uptake in wild-type mice (P<.01)
Conclusions
Radiolabeled alisertib can be synthesized and may have potential for the imaging of AURKA, particularly when AURKA expression is high. However, the exact mechanisms underlying alisertib accumulation need further investigation.Other authorsSee publication
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Daniel Bradley in United States
-
Daniel Bradley
VP, Legal & Deputy Chief Privacy Officer | CIPP/US/E, CIPM, FIP
-
Daniel Bradley
-
Daniel Bradley
Digital Content Creator | Live Streaming Technology | Video Production | Social Media Management | Freelance Writer
-
Daniel Bradley
-
Daniel Bradley
Data Scientist
536 others named Daniel Bradley in United States are on LinkedIn
See others named Daniel Bradley